Table 2.

Co-primary efficacy endpoint: success rate^a (% IGA clear/almost clear, ITT)

	Success rate
	0.3 % A/BPO	Vehicle
Week 1	1	0
Week 2	3.0	0
Week 4	4.3	1.5
Week 8	13*	3.1
Week 12	33.7**	11

A adapalene, BPO benzoyl peroxide, IGA Investigator’s Global Assessment, ITT intent to treat population

* p < 0.05 vs. vehicle

** p < 0.001 vs. vehicle

^aMultiple imputation data; post hoc analysis performed prior to week 12